Intravenous ganaxolone in pediatric super-refractory status epilepticus: A single hospital experience

被引:7
作者
Singh, Rani K. [1 ]
Singh, Rajdeep [1 ]
Stewart, Alejandra [1 ]
Van Poppel, Katherine [1 ]
Klinger, Sarah [1 ]
Hulihan, Joseph [1 ]
Van Heusen, Heather [1 ]
Vaitkevicius, Henrikas [1 ]
Gasior, Maciej [1 ]
机构
[1] Dept Pediat, Atrium Hlth Levine Childrens Pediat Neurol Care, 100 Med Pk Dr Suite 310 E, Concord, NC 28025 USA
关键词
Status epilepticus; Super-refractory status epilepticus; Pediatric; Neurosteroids; CONVULSIVE STATUS EPILEPTICUS; ADJUNCTIVE THERAPY; GABA(A) RECEPTORS; CHILDREN; TRAFFICKING; FREQUENCY; EFFICACY;
D O I
10.1016/j.ebr.2022.100567
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Synaptic GAB(A)A receptor (GABAAR) internalization contributes to the drug resistant nature of super-refractory status epilepticus (SRSE). Ganaxolone is a 3 beta-methylated synthetic analog of the endogenous neuroactive steroid, allopregnanolone, that has positive allosteric modulatory activity on synaptic and extrasynaptic GABA(A) receptors. Ganaxolone is currently in clinical trials to treat rare pediatric seizure disorders and established and refractory SE. Two pediatric patients with SRSE (age 17 and age 7) were treated under emergency investigational new drug (E-IND) applications with intravenous (IV) ganaxolone administered as an initial bolus and a maintenance infusion for up to 4.5 days with intermittent IV boluses as-needed followed by taper on day 5 and transitioned to chronic treatment using ganaxolone suspension. Adjunctive ganaxolone was effective in terminating SRSE in both patients, safely permitting IV anesthetics to be weaned. Seizure control has been maintained after transitioning to enteric ganaxolone. Further investigation of ganaxolone as a safe and effective treatment for SRSE is warranted. (c) 2022 The Authors. Published by Elsevier Inc.
引用
收藏
页数:7
相关论文
共 29 条
[1]  
[Anonymous], 2020, GANAXOLONE INVESTIGA
[2]  
[Anonymous], 2019, ClinicalTrials
[3]   Progress report on new antiepileptic drugs: A summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). II. Drugs in more advanced clinical development [J].
Bialer, Meir ;
Johannessen, Svein I. ;
Koepp, Matthias J. ;
Levy, Rene H. ;
Perucca, Emilio ;
Perucca, Piero ;
Tomson, Torbjorn ;
White, H. Steve .
EPILEPSIA, 2020, 61 (11) :2365-2385
[4]  
Chez M, 2020, AM EPILEPSY SOC ANN
[5]   Interleukin-1β contributes to the generation of experimental febrile seizures [J].
Dubé, C ;
Vezzani, A ;
Behrens, M ;
Bartfai, T ;
Baram, TZ .
ANNALS OF NEUROLOGY, 2005, 57 (01) :152-155
[6]   New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES): State of the art and perspectives [J].
Gaspard, Nicolas ;
Hirsch, Lawrence J. ;
Sculier, Claudine ;
Loddenkemper, Tobias ;
van Baalen, Andreas ;
Lancrenon, Judette ;
Emmery, Michel ;
Specchio, Nicola ;
Farias-Moeller, Raquel ;
Wong, Nora ;
Nabbout, Rima .
EPILEPSIA, 2018, 59 (04) :745-752
[7]   Efficacy and mortality in treatment of refractory generalized convulsive status epilepticus in children: A meta-analysis [J].
Gilbert, DL ;
Gartside, PS ;
Glauser, TA .
JOURNAL OF CHILD NEUROLOGY, 1999, 14 (09) :602-609
[8]   Subunit-specific trafficking of GABAA receptors during status epilepticus [J].
Goodkin, Howard P. ;
Joshi, Suchitra ;
Mtchedlishvili, Zakaria ;
Brar, Jasmit ;
Kapur, Jaideep .
JOURNAL OF NEUROSCIENCE, 2008, 28 (10) :2527-2538
[9]   Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions [J].
Hirsch, Lawrence J. ;
Gaspard, Nicolas ;
van Baalen, Andreas ;
Nabbout, Rima ;
Demeret, Sophie ;
Loddenkemper, Tobias ;
Navarro, Vincent ;
Specchio, Nicola ;
Lagae, Lieven ;
Rossetti, Andrea O. ;
Hocker, Sara ;
Gofton, Teneille E. ;
Abend, Nicholas S. ;
Gilmore, Emily J. ;
Hahn, Cecil ;
Khosravani, Houman ;
Rosenow, Felix ;
Trinka, Eugen .
EPILEPSIA, 2018, 59 (04) :739-744
[10]   Use of Dietary Therapy for Status Epilepticus [J].
Kossoff, Eric H. ;
Nabbout, Rima .
JOURNAL OF CHILD NEUROLOGY, 2013, 28 (08) :1049-1051